A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

April 24, 2025

Study Completion Date

April 24, 2025

Conditions

HealthyPlaque Psoriasis

Interventions

BIOLOGICAL

CAN10

Single dose intravenous or Multiple doses subcutaneously

BIOLOGICAL

CAN10 - Placebo

Single dose intravenous or Multiple doses subcutaneously

Trial Locations (1)

RECRUITING

CRS Clinical Research Services Berlin GmbH, Berlin